Archive for May, 2019

  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical…

    by
  • Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States

    GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…

    by
  • Isofol Reports 58 % Overall Response Rate

    Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…

    by
  • Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study with arfolitixorin

    GOTHENBURG, Sweden, May 8, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from…

    by